Last reviewed · How we verify

sodium thiosulfate solution

Xijing Hospital of Digestive Diseases · Phase 3 active Small molecule Under review

sodium thiosulfate solution is a Antidote Small molecule drug developed by Xijing Hospital of Digestive Diseases. It is currently in Phase 3 development for Cyanide poisoning. Also known as: STS.

Sodium thiosulfate solution works by neutralizing cyanide ions.

Sodium thiosulfate solution is a small molecule intervention used in various clinical trials, including those for Endodontic Disease, Endodontic Inflammation, Renal Transplant, Kidney Transplant, and Gastrointestinal Neoplasms. The exact mechanism of action of sodium thiosulfate solution is currently unknown.

Likelihood of approval
58.3% vs 58.3% industry baseline
If approved by FDA: likely 2028–2030
Steps remaining: NDA/BLA submission
Confidence: High
Why this estimate
  • Baseline phase 3 → approval rate +58.3pp
    Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Predicted approval windows by jurisdiction (conditional on FDA approval)
Regulator Country Likely year Lag vs FDA
FDA US 2028–2030
EMA EU 2029–2031 +0.7 yr
MHRA GB 2029–2031 +0.7 yr
Health Canada CA 2029–2032 +0.9 yr
TGA AU 2029–2032 +1.2 yr
PMDA JP 2029–2032 +1.5 yr
NMPA CN 2030–2033 +2.3 yr
MFDS KR 2029–2032 +1.4 yr
CDSCO IN 2029–2033 +1.8 yr
ANVISA BR 2030–2033 +2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic namesodium thiosulfate solution
Also known asSTS
SponsorXijing Hospital of Digestive Diseases
Drug classAntidote
ModalitySmall molecule
Therapeutic areaToxicology
PhasePhase 3

Mechanism of action

It does this by forming a stable complex with cyanide, which is then excreted from the body. This mechanism is particularly useful in treating cyanide poisoning.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about sodium thiosulfate solution

What is sodium thiosulfate solution?

sodium thiosulfate solution is a Antidote drug developed by Xijing Hospital of Digestive Diseases, indicated for Cyanide poisoning.

How does sodium thiosulfate solution work?

Sodium thiosulfate solution works by neutralizing cyanide ions.

What is sodium thiosulfate solution used for?

sodium thiosulfate solution is indicated for Cyanide poisoning.

Who makes sodium thiosulfate solution?

sodium thiosulfate solution is developed by Xijing Hospital of Digestive Diseases (see full Xijing Hospital of Digestive Diseases pipeline at /company/xijing-hospital-of-digestive-diseases).

Is sodium thiosulfate solution also known as anything else?

sodium thiosulfate solution is also known as STS.

What drug class is sodium thiosulfate solution in?

sodium thiosulfate solution belongs to the Antidote class. See all Antidote drugs at /class/antidote.

What development phase is sodium thiosulfate solution in?

sodium thiosulfate solution is in Phase 3.

What are the side effects of sodium thiosulfate solution?

Common side effects of sodium thiosulfate solution include Hypocalcemia, Hypophosphatemia, Nausea, Vomiting, Diarrhea.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing